ESC 365 - Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy

Open Access

Cardiopulmonary exercise testing as a novel endpoint in clinical trials on ATTR amyloid cardiomyopathy

Session: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Topic: Clinical

Speaker: Doctor A. Porcari (London, GB)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Aldostefano Porcari

Royal Free London NHS Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)

5 presentations

2 followers

6 more presentations in this session

Discussant panel

Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: the VELOCITY study

Speaker: Professor S. Greene (Durham, US)

Efficacy and safety of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms

Speaker: Professor I. Olivotto (Florence, IT)

Pulmonary artery denervation clinical study using the gradient denervation system in heart failure patients with pulmonary hypertension group 2

Speaker: Doctor J. Nunez Villota (Valencia, ES)

Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.

Speaker: Doctor A. Muslin (Watertown, US)

Access the full session

Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension and valvular heart disease

Speakers: Doctor A. Porcari, Professor S. Greene, Professor I. Olivotto, Doctor J. Nunez Villota, Doctor A. Muslin

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources